(Q34295041)

English

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Kenneth J. Pienta

1

object named as

Kenneth J Pienta

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Jean-Pascal Machiels

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dirk Schrijvers

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Boris Alekseev

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Mikhail Shkolnik

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Simon J Crabb

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Susan Li

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Shobha Seetharam

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Thomas A Puchalski

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Chris Takimoto

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Yusri Elsayed

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Fitzroy Dawkins

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Johann S de Bono

13

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

21 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

760-768

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

CCR2 expression correlates with prostate cancer progression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

CCL2 is a potent regulator of prostate cancer cell migration and proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

The measurement of pain from metastatic bone disease: capturing the patient's experience

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9869-8

21 January 2018

Second-line chemotherapy for advanced hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22907596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/22907596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22907596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22907596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22907596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate cancer: a practical approach to current management of recurrent disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22907596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9869-8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34295041&oldid=2196472721"